Scarica l'app Stockscreener
20.24
6.38%
-1.38
Pre-mercato:
20.66
0.42
+2.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNGX Giù?
Forum
Previsione
Tango Therapeutics Inc Borsa (TNGX) Ultime notizie
CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
A Look At Tango Therapeutics (TNGX) Valuation After Wider Losses And Boardroom Changes - Yahoo Finance
Tango Therapeutics is the best performing healthcare stock in March - MSN
Stifel Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Why Tango Therapeutics (TNGX) Is Down 12.4% After Gilead Exit, Wider Loss And Board ChangesAnd What's Next - Sahm
TNGX stock crashes 20% after reporting $0 revenue in Q1 — but analysts still see massive upside - MSN
Tango Therapeutics: 'Hold' On Combination Strategy Shift Of Vopimetostat (NASDAQ:TNGX) - Seeking Alpha
Tango Therapeutics (TNGX) Is Down 10.7% After Pipeline Pivot And Board ChangesHas The Bull Case Changed? - Yahoo Finance
Tango Therapeutics (TNGX) Experiences Significant Decline - GuruFocus
TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits
[SCHEDULE 13G/A] Tango Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
Nextech Crossover reports 7.27M-share stake in Tango Therapeutics (TNGX) - Stock Titan
Jefferies downgrades Tango Therapeutics (TNGX) - MSN
Mizuho Raises Price Target on Tango Therapeutics to $30 From $20, Keeps Outperform Rating - Moomoo
TNGX Maintained by Mizuho -- Price Target Raised to $30 - GuruFocus
Leerink Partners Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Tango Therapeutics Shares Fall After Jefferies Downgrade - Moomoo
Mizuho Securities Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Woodline Partners reports 8.0M-share stake in Tango Therapeutics (TNGX) - Stock Titan
Tango Therapeutics Price Target Raised to $30.00/Share From $20.00 by Mizuho - Moomoo
A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $27 to $55 - Moomoo
RTW Funds disclose 13.3M shares in Tango Therapeutics (NASDAQ: TNGX) - Stock Titan
This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Vanguard Group Inc. Has $59.81 Million Holdings in Tango Therapeutics, Inc. $TNGX - MarketBeat
Piper Sandler downgrades Tango Therapeutics stock rating on strategy shift By Investing.com - Investing.com Australia
Piper Sandler downgrades Tango Therapeutics stock rating on strategy shift - Investing.com UK
Piper Sandler downgrades Tango Therapeutics (TNGX) - MSN
TNGX Downgraded by Jefferies -- Price Target Raised to $27 - GuruFocus
TNGX stock hits record high on inking collaboration deal with ERAS - MSN
Mizuho raises Tango Therapeutics stock price target on pipeline progress By Investing.com - Investing.com Nigeria
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $30.1, Implies 18% Upside - TradingView
Mizuho raises Tango Therapeutics stock price target on pipeline progress - Investing.com
Tango Therapeutics price target raised to $33 from $19 at Wedbush - TipRanks
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $27.4, Implies 7% Upside - TradingView
Tango Therapeutics Is Maintained at Outperform by Wedbush - Moomoo
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $26, Implies 2% Upside - TradingView
Wedbush Adjusts Price Target on Tango Therapeutics to $33 From $19, Maintains Outperform Rating - Moomoo
Tango Therapeutics downgraded to Hold from Buy at Jefferies - TipRanks
Jefferies downgrades Tango Therapeutics stock rating on valuation - Investing.com
Jefferies downgrades Tango Therapeutics stock rating on valuation By Investing.com - Investing.com Australia
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $24.8, Implies 3% Downside - TradingView
Tango Therapeutics (TNGX) Zero Q1 Revenue Tests Bullish 56.6% Growth Narrative - Sahm
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):